/ /

  • linkedin
  • Increase Font
  • Sharebar

    How has ophthalmology changed in 2016?

     

    "What advances are you anticipating in the coming year?"

    Dr. McDonnell greatly anticipated seeing how the first approved corneal inlay (KAMRA inlay, AcuFocus) would fare in the marketplace. Since then, another inlay (Raindrop Near Vision Inlay, ReVision Optics) has also been capturing surgeons’ attention.

    In addition, Dr. McDonnell's hope that corneal crosslinking (CXL) would make its entrance into the U.S. market finally came true this year. Since its approval, CXL has shown to be a safe, effective procedure for treatment of keratoconus and corneal ectasia. Various methods of the CXL procedure, such as photorefractive intrastromal crosslinking (PiXL), epi-on CXL, and accelerated CXL, have also gained in popularity and use in the United States.

    Dr. Olson could not wait to have new options for dry eye products. You may have been living under a rock if you did not hear Shire’s new dry eye drug, Xiidra, was approved by the FDA this year for the treatment of the signs and symptoms of dry eye disease. You can read about the results of the OPUS-3 study here.

    Jolie Higazi
    Jolie is the Content Specialist for Ophthalmology Times. She can be reached at [email protected]

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results